Acetaminophen for Prevention and Treatment of Organ Dysfunction in Critically Ill Patients With Sepsis: The ASTER Randomized Clinical Trial

• Published in: JAMA : the journal of the American Medical Association Vol. 332; no. 5; p. 390
• Main Authors: Ware, Lorraine B, Files, D Clark, Fowler, Alpha, Aboodi, Michael S, Aggarwal, Neil R, Brower, Roy G, Chang, Steven Y, Douglas, Ivor S, Fields, Scott, Foulkes, Andrea S, Ginde, Adit A, Harris, Estelle S, Hendey, Gregory W, Hite, R Duncan, Huang, Weixing, Lai, Poying, Liu, Kathleen D, Thompson, B Taylor, Matthay, Michael A
• Format: Journal Article
• Language: English
• Published: United States 06.08.2024
• Subjects: Acetaminophen - adverse effects; Acetaminophen - therapeutic use; Aged; Analgesics, Non-Narcotic - adverse effects; Analgesics, Non-Narcotic - therapeutic use; Critical Illness; Double-Blind Method; Female; Hemoglobins - analysis; Humans; Male; Middle Aged; Multiple Organ Failure - etiology; Multiple Organ Failure - prevention & control; Organ Dysfunction Scores; Renal Replacement Therapy; Respiration, Artificial; Sepsis - complications; Sepsis - drug therapy
• ISSN: 1538-3598
• DOI: 10.1001/jama.2024.8772

Acetaminophen (paracetamol) has many pharmacological effects that might be beneficial in sepsis, including inhibition of cell-free hemoglobin-induced oxidation of lipids and other substrates. To determine whether acetaminophen increases days alive and free of organ dysfunction in sepsis compared with placebo. Phase 2b randomized, double-blind, clinical trial conducted from October 2021 to April 2023 with 90-day follow-up. Adults with sepsis and respiratory or circulatory organ dysfunction were enrolled in the emergency department or intensive care unit of 40 US academic hospitals within 36 hours of presentation. Patients were randomized to 1 g of acetaminophen intravenously every 6 hours or placebo for 5 days. The primary end point was days alive and free of organ support (mechanical ventilation, vasopressors, and kidney replacement therapy) to day 28. Treatment effect modification was evaluated for acetaminophen by prerandomization plasma cell-free hemoglobin level higher than 10 mg/dL. Of 447 patients enrolled (mean age, 64 [SD, 15] years, 51% female, mean Sequential Organ Failure Assessment [SOFA] score, 5.4 [SD, 2.5]), 227 were randomized to acetaminophen and 220 to placebo. Acetaminophen was safe with no difference in liver enzymes, hypotension, or fluid balance between treatment arms. Days alive and free of organ support to day 28 were not meaningfully different for acetaminophen (20.2 days; 95% CI, 18.8 to 21.6) vs placebo (19.6 days; 95% CI, 18.2 to 21.0; P = .56; difference, 0.6; 95% CI, -1.4 to 2.6). Among 15 secondary outcomes, total, respiratory, and coagulation SOFA scores were significantly lower on days 2 through 4 in the acetaminophen arm as was the rate of development of acute respiratory distress syndrome within 7 days (2.2% vs 8.5% acetaminophen vs placebo; P = .01; difference, -6.3; 95% CI, -10.8 to -1.8). There was no significant interaction between cell-free hemoglobin levels and acetaminophen. Intravenous acetaminophen was safe but did not significantly improve days alive and free of organ support in critically ill sepsis patients. ClinicalTrials.gov Identifier: NCT04291508.